Skip to content Skip to footer
Subscribe Now
Viewpoints_Douglas Onsi
VIEWPOINTS

PharmaShots Interview: Leap Therapeutic’s Douglas Onsi Shares Insight on its Lead Candidate, DKN-01

In an interview with PharmaShots, Douglas Onsi, CEO and President of Leap Therapeutics shares insights on the clinical data of DKN-01 along with its mechanism. He also highlights the company's growth, plans, goal etc.Shots:DKK1 is a secreted protein that modulates cell signaling pathways known as the Wnt signaling pathways, as well as the PI3 kinase…
April 14, 2021

Read more

Viewpoints_Tej Patel
VIEWPOINTS

PharmaShots Interview: Fluxergy’s Tej Patel Shares Insight on Multimodal Diagnostic System

In an interview with PharmaShots, Tej Patel, CEO of Fluxergy shared his views on Fluxergy's CE Marking and how it will democratize healthcare while creating better clinical outcomes.Shots:Fluxergy's One-hour COVID-19 test requires less than 2-3 minutes of hands-on time and provides lab-quality RT-PCR test results within an hour.The Fluxergy analyzer is a compact, high-density…
April 13, 2021

Read more

Viewpoints_Dr. Gail McIntyre
VIEWPOINTS

PharmaShots Interview: Aravive’ s Dr. Gail McIntyre Shares Insight on AVB-500 and its Potential Against ccRCC

In an interview with PharmaShots, Dr. Gail McIntyre, CEO of Aravive shared her views on the AVB-500, its potential against ccRCC, and the design of the clinical trial evaluating the therapy. He also shed light on epidemiology of Clear Cell Renal Cell Carcinoma.Shots:AVB-500 is being evaluated in ccRCC, has been tested in preclinical models of…
April 9, 2021

Read more

Viewpoints_Marc Meachem
VIEWPOINTS

PharmaShots Interview: Marc Meachem Shares Insight on the ViiV’s 2021 Commitment to the Community

In an interview with PharmaShots, Marc Meachem, Head of US External Affairs at ViiV Healthcare shared his views on the company's approach towards the community. He also shed light on the grants and funding received for the betterment of HIV patients.Shots:ViiV Healthcare is doubling its community investments in 2021 with the goal of disrupting the enduring…
April 7, 2021

Read more

Viewpoints_Dietrich Stephan
VIEWPOINTS

PharmaShots Interview: NeuBase Therapeutics’ Dietrich Stephan Shares Insight on its Approach to Genetic Medicine

In an interview with PharmaShots, Dietrich Stephan, Ph.D., CEO of NeuBase Therapeutics shared his views on the importance of preclinical in vivo data for PATrOL-enabled anti-gene for myotonic dystrophy type 1.Shots:NeuBase announced in vitro and in vivo data for its DM1 program, demonstrating the potential of its genetic medicine platform to target the disease-causing…
April 6, 2021

Read more

Viewpoints_Marie Schiller
VIEWPOINTS

PharmaShots Interview: Eli Lilly’s Marie Schiller Shares Insight on the Collaboration with Welldoc on New Version of BlueStar App

In an interview with PharmaShots, Marie Schiller Vice President of Product Development for Connected Care and Insulins at Lilly shared her views on its collaboration with Welldoc to integrate Welldoc's insulin management technology into Lilly's connected insulin solutions.Shots:Lilly and Welldoc are teaming up to create a new version of Welldoc's BlueStar app which will be integrated…
April 5, 2021

Read more

Insights+ Key Biosimilars Events of March 2021
INSIGHTS+

Insights+ Key Biosimilars Events of March 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of March, Samsung Bioepis Initiated P-I Study of SB17…
April 1, 2021

Read more

Viewpoints_Mark Erlander
VIEWPOINTS

PharmaShots Interview: Cardiff Oncology’s Mark Erlander Shares Insight on the P-I Data of Onvansertib for Metastatic Colorectal Cancer

In an interview with PharmaShots, Mark Erlander, CEO of Cardiff Oncology shared his views on the data presented at the ASCO-GI Conference, P-Ib results of Onvansertib, what these results meant for the patients with this aggressive type of mCRC, and the company's other ongoing programs for Onvansertib, including metastatic castration-resistant prostate cancer and AMLShots:The data presented at ASCO-GI showed…
March 31, 2021

Read more

Viewpoints_Dr. Sezer, Peter C. Adamson and Israel Lowy
VIEWPOINTS

PharmaShots Interview: Dr. Sezer, Peter C. Adamson and Israel Lowy Share Insight on the US FDA’s Approval of Libtayo (cemiplimab) in Patients with NSCLC with High PD-L1 Expression

Shots:In an interview with PharmaShots, Dr. Ahmet Sezer,  Sanofi's Peter C. Adamson, and Regeneron's Israel Lowy shared their views on the US FDA's approval of Libtayo and the data supporting the approval.Regeneron and Sanofi received the US FDA's approval for Libtayo for the 1L treatment of patients with advanced NSCLC whose tumors have high PD-L1 expression (tumor proportion score =50%), as…
March 30, 2021

Read more

Viewpoints_Nirav Desai
VIEWPOINTS

PharmaShots Interview: Takeda’s Nirav Desai Shares Insight on Data of TAK-721 Presented at ACG 2020

In an interview with PharmaShots, Nirav Desai, Global Clinical Development Lead at Takeda shared his views on TAK-721 data presented at ACG 2020 and its implications for patients and HCPs. The presentation includes post hoc analyses from a 12-week, randomized, double-blind, placebo-controlled Phase 3 clinical trial that investigated the safety and efficacy of BOS in patients with EoE 11 to 55 years…
March 29, 2021

Read more

Load more